Effects of a novel formulation of fluocinonide 0.1% cream on skin barrier function in atopic dermatitis.

about

Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.

P2860

Q35077866-9D1BC18F-3649-482A-B551-294ED95E55B9

P2860

Effects of a novel formulation of fluocinonide 0.1% cream on skin barrier function in atopic dermatitis.

Item

http://www.wikidata.org/entity/Q42688441

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Effects of a novel formulation ...... function in atopic dermatitis.

@en

Effects of a novel formulation ...... function in atopic dermatitis.

@nl

type

Item

label

Effects of a novel formulation ...... function in atopic dermatitis.

@en

Effects of a novel formulation ...... function in atopic dermatitis.

@nl

prefLabel

Effects of a novel formulation ...... function in atopic dermatitis.

@en

Effects of a novel formulation ...... function in atopic dermatitis.

@nl

P1476

Effects of a novel formulation ...... function in atopic dermatitis

@en

P2093

Eric L Simpson

http://www.w3.org/2001/XMLSchema#string

Matthew T Woods

http://www.w3.org/2001/XMLSchema#string

Peter A Brown

http://www.w3.org/2001/XMLSchema#string

Shahana F Baig-Lewis

http://www.w3.org/2001/XMLSchema#string

P2860

Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis

Systematic review of treatments for atopic eczema.

Clinical applications of visual analogue scales: a critical review.

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

Transepidermal water loss reflects permeability barrier status: validation in human and rodent in vivo and ex vivo models.

Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities.

In vivo determination of the skin atrophy potential of the super-high-potency topical corticosteroid fluocinonide 0.1% cream compared with clobetasol propionate 0.05% cream and foam, and a vehicle.

Translating the science of quality of life into practice: What do dermatology life quality index scores mean?

P304

171-176

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21283922

http://www.w3.org/2001/XMLSchema#string

P932

3156681

http://www.w3.org/2001/XMLSchema#string

Effects of a novel formulation of fluocinonide 0.1% cream on skin barrier function in atopic dermatitis.

about

P2860

P2860

Effects of a novel formulation of fluocinonide 0.1% cream on skin barrier function in atopic dermatitis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932